Skip Navigation

European Heart Journal 1995 16(7):903-908;
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by FERRARA, N.
Right arrow Articles by RENGO, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FERRARA, N.
Right arrow Articles by RENGO, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Protective effect of beta-blockade on dipyridamole-induced myocardial ischaemia

Role of heart rate

N. FERRARA, F. COLTORTI, D. LEOSCO, S. SEDERINO, P. ABETE, P. CACCESE, P. LANDINO, G. LONGOBARDI*, R. VERDE and F. RENGO

Istituto di Medicina Interna, Cardiologia, Chirurgia Cardiovascolare, Cattedra di Geriatria, Facolta' di Medicina e Chirurgia, Universita' degli Studi di Napoli "Federico II" Naples
*Fondazione Clinica del Lavoro-I.R.C.C.S. Campoli MT (BN) Italy

revised 29 September 1994; accepted 28 October 1994.

Correspondence: Nicola Ferrara, MD, Ist. Med. Interna, Cardiologia, Chirurgia Cardiovascolare, Cattedra di Geriatria, II Facolta' di Medicina e Chirurgia, via S. Pansini, 5 – 80131 Naples, Italy.

Abstract

This study was designed to investigate the effect of heart rate changes on dipyridamole echocardiographic tests in patients with coronary artery disease treated with propranolol.

We prospectively studied 12 patients (8 men and 4 women; mean age 56.5 ± 8.7 years) selected by: (a) angiographic evidence of significant coronary artery disease; (b) adequate echocardiographic window; (c) positive dipyridamole echocardiography test results in baseline conditions (step I); (d) test reproducibility in the absence of treatment; (e) negative dipyridamole echocardiography test results after 7 days of treatment with propranolol (120 mg. day{theta}1) in twice divided doses daily (step II).

In all patients treated with propranolol, dipyridamole echocardiographic testing was repeated 24 h after the last negative test. In these patients, transoesophageal atrial pacing was performed at peak dipyridamole infusion to increase heart rate to values similar to those observed at baseline (step III). At baseline, heart rate and rate-pressure product were significantly lower in patients treated with propranolol (–{theta}20.3% and –{theta}22.5% in group II, P<0–001 vs step I; –{theta}24.3% and –{theta}26.4% in group III, P<0.05 vs step I), but the different treatments did not produce significant differences in systolic and diastolic blood pressure. At peak dipyridamole infusion, heart rate and rate-pressure product increased with either placebo or propranolol treatments with respect to baseline, while remaining significantly lower with propranolol as compared to placebo ( –{theta}29.6% and –{theta}29.5% in step II, P<0001). During treatment with propranolol plus transoesophageal pacing to maintain heart rate at values attained with placebo, the rate-pressure product did not change significantly with respect to placebo, nor did systolic blood pressure. Transoesophageal atrial pacing performed during propranolol treatment to restore heart rate to baseline values did not affect the dipyridamole echocardiographic test in eight patients (group I), and induced transient wall abnormalities in four patients (group II) (P={theta}ns).

Our data suggest that the anti-ischaemic effect of propranolol in man is not correlated only to reduction of heart rate.

Key Words: Beta-adrenoceptor blockade • dipyridamole • atrial pacing • myocardial ischaemia • echocardiography


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart JHome page
F. Rigo, R. Sicari, S. Gherardi, A. Djordjevic-Dikic, L. Cortigiani, and E. Picano
The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo
Eur. Heart J., January 1, 2008; 29(1): 79 - 88.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. Cortigiani, F. Rigo, S. Gherardi, R. Sicari, M. Galderisi, F. Bovenzi, and E. Picano
Additional Prognostic Value of Coronary Flow Reserve in Diabetic and Nondiabetic Patients With Negative Dipyridamole Stress Echocardiography by Wall Motion Criteria
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1354 - 1361.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Sicari, L. Cortigiani, R. Bigi, P. Landi, M. Raciti, E. Picano, and for the Echo-Persantine International Cooperative
Prognostic Value of Pharmacological Stress Echocardiography Is Affected by Concomitant Antiischemic Therapy at the Time of Testing
Circulation, May 25, 2004; 109(20): 2428 - 2431.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.